A swipe-through post sets the two GLP-1 drugs side by side, covering how each works, common side effects and key trial results.
Recap by typeshit. Post by Facebook on Facebook.
A comment-for-link Instagram post saying trials of semaglutide, tirzepatide and retatrutide showed up to 28% weight loss. Little detail beyond that.
Real-world records shown at EASD 2026 had 24.1% of tirzepatide users losing 15% or more in a year, versus about 9% on semaglutide, GlobalData reports.
Survey data on 3,615 US adults showed about 30% lower odds of GLP-1 use among cancer survivors, despite more heart and kidney disease. Causes remain unclear.
11:38
RMZ digs into why weight loss results on tirzepatide vary so widely, with some people losing double what others do.
Industry executives say India's contract drug makers are moving past cheap small molecules into more complex products, including peptides.
A Mayo Clinic Florida study of over 3,800 women found 9.8% vs 8.2% weight loss at 9 months with HT on semaglutide. Researchers say it shows association, not cause.
Loading…